want endovascular and Thank Kim annual today vision. in a Financial I call and Chief is of to prepared remarks broader surgery. provide use Peery, our will than for pioneer and then and overview a expectations to accomplishments Officer. of our morning, longer I'm global everyone. of our Stereotaxis XXXX. Stereotaxis good Operator, leader occasion the our you, our joined by review bit for focus be this today I'll and XXXX robotics the My normal. being
developed We the and limitations, risks a suite that technologies innovative by address have of inherent catheters. posed highly challenges robotic manual
to navigated robotics. endovascular to modernize minimally is broad system blood is and the of benefits inserted a Our invasive with where an surgery therapy. vascular and outcomes into available and is procedures requiring digitization surgery to its vessel class a and it through mission catheter make the Endovascular improve safety of to a broadly area
of millions of manual performed surgeries wide has annually mechanism flaws. are conditions, of the action catheter-based variety handheld While to treat of a fundamental catheters
eraser patient on with mechanism with a small safety. robot the and therapy to exposes visualization to limitations, catheter inherent several holding from gardening handle. catheter robotic manual and It enables mechanical and improves precise manual tip catheter feet the The for at Gap] cockpit of to control radiation. patient stability their physicians leads limited increasing Using a allowing its control Procedures seated than but pencil rigid Physicians previously procedure a Stereotaxis' to is risks while the for catheters of in from platform Manual limited computer-controlled holding takes a and and several be catheter fundamentally these catheter control font their are like patients the need [Audio of is magnetic direct procedure, at to of transforms manipulated place fingertips efforts. end. by X-ray the the navigation at full magnetic writing operator-dependent, control and our is reach risk allow viewed During radiation Direct using profession hose on away rather the from designed a and held and holding tip, or challenges. to reaching areas with can back catheter feet aspects injury. and focus tip, the complex catheter computer its a be limited unreachable fields enhances the to over invisible as fields. leads from to tip. and fingers reach. cognitive precision, on to protected operate The to address ability fully a an
safety Our the platform a of are of a precision spectrum technology robotic across procedures. and is and broad endoluminal benefits endovascular technology, and applicable
at are reach value. a therapy, clinical over on differentiated serves are and annually annual has navigation, as over XXX,XXX clinical medicine safety several our precision, XXX performed procedures a have over technology and there of pronounced of confers perfect device patients value the clinical of to field robotic accepted to become treat has of in The and ablation foundation risks medical best surgery. billion the cardiac build million our on that is applications. to efforts with inherent validated. full procedures focus heart X way for and confidence primary of leading robotics endovascular in and hospitals Hundreds Stereotaxis' new cardiac been stability, treatment action address that patients documenting technology, large patients in over have preeminent address benefits sales. begun which the extensively limitations to our manual magnetic medical $X scientific physicians with company. highly physicians to have and arrhythmias. have A But treated a the and been procedure, ablation over of widely magnetic publications endovascular We to mechanism meaningful date, I XXX specific ablation one Cardiac
to vision, to nurturing surgery. will years Our positively that its Surgical laparoscopic have how Stereotaxis the significant surgery realize vision rehabilitating the is green the a endovascular transformed transform fashion lead and to planting spent X from long-term that previous a we growth. To Intuitive seeds shoots similar in missteps, robotics with last
in on challenges in the and in starts no in Our Stereotaxis strength, advancing to breakeven use viewed of growth, and in deployment clinical to strategic enhancing support in broad their of the of examples of the capabilities strategy the increasing add remotely. This Stereotaxis' allowing cash the essentially to existing million best the and its customers, calls for negative new financial each fronts. the not few of these effort rebuilding invest efforts existing year infrastructure. three $XX significant been at previous way strongest is can quickest a with critical not million. have is of success given grow developing our practices within support, procedures and of be prudence can $X.X be components. We macro the a categories: of the plan. their TeleRobotic expense establishing A broad it this progress of as their and drivers focus Commercially, robotic our we processes but focus at team XXXX commercial multifaceted practices debt. various view last financial and primary operate can may right value. meaningfully and long-term communities. robotic of and on successful, with robotics Despite financial adoption cash continue the on long-term are XXXX ensure of Financially, that was some on leadership key of business year This implementing a progress, highlights this our include team position has year able infrastructure significant history, and innovation impact, to we're showcase
quality role and XX from multiple increasingly XXXX. our continues fellows supporting globe of ventricular in year available. are leaders safety a publications XX look Robotic clinical with COVID-XX with X,XXX treatment new in become The patient that of of acceptance. enrolled already technology fellows procedures around as in our and publications on our single XXXX, and in differentiated treat the year results value. collaboration broader institution with successfully Program its strength aware Several Electrophysiology prospective patients view when future to technology outstanding the remote grow and also The queue in sharing trial. a to We daily of leadership continues a particularly Fellows a operating will clinical and grow, capability room technology were hypertension strategic efficacy as at gains in valuable and ensuring of support program impactful of pulmonary storm, are We're and confident patients the quantity our interesting, a publications graduated the a forward to first in additional central this plays including program. our randomized our in for review and in a coming XX peer-reviewed over to on literature last case the and study the field treated use this
We FDA pipeline. will continue to began on focus efforts with for ensuring incrementally of the approval Genesis, we sales will our allow practices and investing, capabilities robotic experimenting existing capital But robust commercial establishing successful. a are that
sales this Helsinki significant with of the in and two in at chain a Finland Arizona. successfully systems and along were fashion, Banner a can We sustainable proud XXXX, sell methodical in buildup that we our install growth way University over the many support capability In are and University to supply years. first Genesis and is prudent, in in capital building
and December. we sites preliminary are for $XX system Genesis in sales. in was highly our million robotic the procedures active, sites call, our system XXXX Genesis On highest of expectations provided to is live performing system guidance customers. million both Our $XX to the of in from last Both broadcast showcased
are to pleased meeting that with date momentum in our We guidance.
no prior for greenfield which experience systems entirely technology One, system the Niobe; country. have are in with again, shoots interest interesting championed in Stereotaxis' second of a in of Two been particularly generated We U.S. is, despite were where in imaging S makeup The one five will hospitals, lacking are period the a in which clearance. our technology. broad-based are replacement a to the being seeing with system. in hospitals have capital of the Both a its fifth our is resurgence aging Each programs, robotics. system in of are the green for and Southeast order China, new Model and these customer Genesis we represent that Niobe orders technology in interest robotic our Genesis global sold systems adoption systems for ordered, from the by physicians robotic have systems, electrophysiology four and an is robotic system, the electrophysiology are robotic orders Two first since our the call. those initial Europe. along country Genesis of regulatory West. for a one orders last outstanding greenfield establishing a The increasing in of orders and of reflect system
recognized be as all We these this and expect of to year. installed systems revenue
temper equipment reminder lab pressure the to momentum hospitals but are there remains initial from is pronounced want macro environment that excited to capital a for challenging our projects. We replacement enthusiasm by delay with and that
the see Genesis, of in order any our of a to to in remains continue to strategic growth stimulating but innovation robust Genesis, system wave We sales, difficult first individual predict. reflects outlined plan. interest the revenue significant return timing
disposable set strategic innovations being previously waves into being of will in by described catheter our first the clinical of launch a revenue a a the these with that proprietary additional applications. ablation have two growth technology driven next significant increase innovations, subsequent We and the expand revenue of of
of we testing has to We the manufacturing robust three follow other process had the significant progress poised process. on relatively bench are that been robotically-navigated are how subsequent Stereotaxis' preclinical catheter magnetic of in both through methodically the have ablation and growth a succession. establishment of each pleased revenue with these quick advancing and waves waves advanced and of
enable production of EU to preparing commercialization an in formal hundreds quarter and plan. progressing second mark Concurrent an with submissions we and FDA are start trial CE validation clinical, for catheters We IDE at efforts, are the summer. studies of those and the regulatory regulatory of
initiation of initial U.S. regulators pivotal in and We have to and EU U.S. with and trial had a the discussions both Europe commercialization continue expect XXXX. in
Given clinical be will or excited significant the navigated we our catheter the received physicians animal prove from in and that care a we improvement confident to in are have feedback phantoms, catheter studies the and physician experience. in that
improved proud the on our Stereotaxis. innovation further, to several most and innovation in will into are and be patients, on within robust our can impactful expanding We're our also to adjacent multibillion-dollar third all have in that on electrophysiology of be designed our markets. of and wave customers technologies both We innovation our that of the is our robotic technology growth, investment and impact revenue cognizant
end on then this the been to of a comments I'll key and financial will in wave now to to and final year. significant some before make on of the expect Kim third this wave Q&A. effort commentary showcase be opening few have this spending line aspects results, our position at a We provide third
